CVasThera
Private Company
Funding information not available
Overview
CVasThera is a Paris-based, privately-held biotech founded in 2016 by seasoned pharmaceutical executives. It operates as a project accelerator, identifying and developing small molecule drug candidates, primarily in cardiovascular and gastrointestinal diseases, through a model built on expert guidance, funding access, and strategic intellectual property management. The company's pipeline includes partnered and internal programs at pre-clinical stages, supported by research grants and collaborations with academic and industry partners. Its core value proposition is de-risking and accelerating early-stage biopharmaceutical projects for partners and its own portfolio.
Technology Platform
Operational platform based on four pillars: 1) Access to integrated scientific expertise for early decision-making, 2) Access to funding to reduce financial hurdles, 3) Adaptive protocols for fast clinical proof-of-concept, and 4) Strategic intellectual property management. This model is applied to accelerate and de-risk early-stage drug projects.
Opportunities
Risk Factors
Competitive Landscape
CVasThera competes with other biotech accelerators, venture capital-backed incubators, and consulting firms that provide drug development services. For its internal Crohn's disease asset, it competes with numerous biopharma companies developing novel IBD therapies. Its differentiation lies in the deep, hands-on pharmaceutical development experience of its founders and its integrated four-pillar operational model.